The FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice regulations for active pharmaceutical ingredients.
Jan. 23—THURSDAY, Jan. 23, 2025 (HealthDay News) — The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about significant deviations from Current Good ...
French pharmaceutical giant Sanofi has received a warning letter from the U.S. Food and Drug Administration following an inspection at its drug manufacturing facility in Framingham.
THURSDAY, Jan. 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about ... plant in Framingham, Massachusetts. On Jan. 15, 2025 ...
Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. drug ingredients plant tied to its longstanding subsidiary Genzyme.
The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility in Massachusetts.
THURSDAY, Jan. 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about significant ... at their Genzyme manufacturing plant in Framingham, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results